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Developing innovative delivery strategies remains an ongoing task to improve both eﬃcacy and safety of drug-based therapy.
Nanomedicineisnowapromisingﬁeldofinvestigation,risinghighexpectancies fortreatingvariousdiseasessuchasmalignancies.
Putting drugs into liposome is an old story that started in the late 1960s. Because of the near-total biocompatibility of their lipidic
bilayer, liposomes are less concerned with the safety issue related to the possible long-term accumulation in the body of most
nanoobjectscurrentlydevelopedinnanomedicine.Additionally,noveltechniquesandrecenteﬀortstoachievebetterstability(e.g.,
through sheddable coating), combined with a higher selectivity towards target cells (e.g., by anchoring monoclonal antibodies or
incorporating phage fusion protein), make new liposomal drugs an attractive and challenging opportunity to improve clinical
outcome in a variety of disease. This review covers the physicochemistry of liposomes and the recent technical improvements in
the preparation of liposome-encapsulated drugs in regard to the scientiﬁc and medical stakes.
1.Introduction
Liposomes are nearly spherical, microparticulate, multil-
amellar or unilamellar bilayer vesicles made from lipids
alternating with aqueous sections [1]. Their biochemical
s t r u c t u r ei sv e r ym u c hs i m i l a rt ot h a to fn o r m a lh u m a n
cellular membranes. They also bear resemblance to micelles,
although there are some key diﬀerences between them
(Figure 1).TheywereﬁrstdiscoveredbyDrAlecD.Bangham
in 1961 at Babraham University of Cambridge [2].
Becauseoftheaforementionedsimilaritytonaturalcom-
ponents as well as their ability to enfold various substances,
scientists hypothesized that liposomes complied with the
requirements of an almost ideal drug carrier system. So, for
the last 40 years liposomes have been studied thoroughly and
are actually celebrated for their biological and technological
advantages as eﬀective carriers for biologically active sub-
stances, both in vitro and in vivo. Naturally, they continue
to constitute a ﬁeld of intense research and are considered to
be the best drug carrier system known yet. Notable progress
hasbeenmadeduringthelastdecadeandvariousbiomedical
applications of liposomes have already been approved for
public use or are on the verge of commercialization [3].
2. GeneralDescription
All liposomes have in common a compartmental structure
which gives them the ability to function as storage and
carrier systems for various substances. The use of liposomes
as carrier systems is based on the fact that all liposomal
content is protected against naturally occurring phenomena,
suchasenzymicdegradationandimmunologicandchemical
inactivation. When the desired molecules are imported to
the liposomes, at least one interjected lipidic layer insulates
them from their environment. Other than that, the lipidic
composition of the liposomal membranes guarantees their
biocompatibility and biodegradability [4]. Last but not least,
liposomal formulation allows for poorly soluble lipophilic
and amphiphilic drugs to be better solubilized in aqueous
solutions [5]. To summarize, liposomes can store, protect,
and transfer substantial quantities of medicines while being
well tolerated by the receiving organism. These unique traits2 ISRN Pharmaceutics
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Figure 1: Aspects of liposomes and micelles. A representation of
the steric organization of a liposome (left) and a micelle (right).
Liposomes have a lipidic bilayer (bottom) whereas micelles are
constructed only by one lipid layer that has its apolar section turned
inwards while its polar heads interact with the environment. As a
result, the enclosed space in micelles is much more conﬁned to that
available in liposomes.
provide for an upgraded biopharmaceutical proﬁle through
reduced toxicity and favourable pharmacokinetic behaviour
and an improved therapeutic index in comparison to the
free-form drug.
3.Physiochemistryof Liposomes
The eﬃcacy of liposomes as a colloidal storage and carrier
system for biologically drastic substances greatly depends on
the physiochemical properties of their membranes and the
nature of the enclosed agent. The former include their size,
surface charge, lipidic organization, and chemical constitu-
tion, among others [6]. Hereinafter follows a generalized
presentation of the physical and chemical traits of liposomes.
3.1. Chemical Traits. Liposomes are composed of lipids.
Lipids are amphiphile biomolecules that have either a
charged or neutral polar head and at least one hydrophobic
aliphatic chain. They are generally immiscible to aqueous
solutionsbutverysolubletoorganicsolvents.Althoughthere
are many types of lipids, liposomes are mainly consisted
of phospholipids that have a hydrophilic head and two
apolar hydrophobic chains (Figure 2). When dispersed in
aqueoussolutions,theirstericorganizationaimstominimize
the interactions between the hydrophobic chains and water
molecules,thusspontaneouslyformsbilayermembranes,the
liposomes [7]. Inside these membranes, ions or molecules
can be encapsulated, provided that they are present during
the formulation process. The ﬁnal arrangement of lipids
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Figure 2:Thefundamentalorganizationofliposomes.Inthisﬁgure
one can observe the fundamental organization of liposomes with
one bilayer and the direction that phospholipids adopt in order to
form it.
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Figure 3: Departmental structure and charge distribution of a
typical phosphoglyceride. On the left is the polar phosphoric group
esteriﬁed to the hydroxyl group of an alcohol. On the right is the
apolar aliphatic chains esteriﬁed to the central moiety, which is a
glycerol.
depends on their concentration, temperature, and geometric
form.
3.1.1. Anatomy of a Phospholipid. A typical phospholipid is
divided into four sections (Figure 3)[ 8]:
(1) the fatty acid section,
(2) a moiety onto which the fatty acids can be attached,
(3) a phosphate group,
(4) an alcohol attached to the phosphate.
The fatty acid section acts as a hydrophobic fence while
the remaining part of the molecule is hydrophilic and can
thus interact with the aqueous surrounding of the liposome.
The moiety onto which the fatty acids can be attached is usu-
ally glycerol but can also be sphingosine [9, 10]. Laboratory
liposomal formulation uses glycerol-based phospholipids,
also called phosphoglycerides. Glycerol’s hydroxyl groups of
C 1a n dC 2a r ee a c he s t e r i ﬁ e dt ot h ec a r b o x y lg r o u po fa
fatty acid. The C3 hydroxyl group is esteriﬁed to a phosphate
group which is in turns esteriﬁed to the hydroxyl group of
an alcohol. This alcohol group usually belongs to choline,
serine, and glycerol but can be also provided from inositol orISRN Pharmaceutics 3
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Figure 4: Examination of a lipidic bilayer. The longer apolar chains
are stacked in the internal department of the bilayer. Because of
their length, they are able to move across the surface of their lipidic
sheet, granting the membrane with a valuable ﬂuidity. The darker
spots represent the polar heads of each lipid.
ethanolamine. Eukaryotes and bacteria membrane lipids are
usually phospholipids like phosphatidyl ethanolamine (PA)
and phosphatidyl choline (PC).
3.1.2. Lipidic Hydrophobicity. It is a fact that lipids have a
strong tendency to form membranes. One has to underline
that this happens because of their amphipathic nature. On
one hand, their polar heads promote aqueous interactions;
on the other hand, their long apolar aliphatic chains prefer
to interact with each other, stacking themselves side by side.
In order to serve both needs, the simplest solution is the
formation of a lipid bilayer consisted of two lipid sheets.
The hydrophobic chains of each sheet face each other and
compose a lipophilic internal compartment that works as a
permeability barrier, both inwards and outwards (Figure 4).
The forces behind the rapid impulsive formation of these
double lipid sheets are hydrophobic interactions. They lower
the system’s energy by enveloping the aliphatic chains and
placing them next to each other thus extruding any water
molecules that are unfavourably surrounding hydrophobic
regions. Van der Waals forces strengthen this architecture by
keeping together the long hydrocarbon tails. Finally, polar
interactions and hydrogen bonds generated between the
polar heads of lipids and water molecules of the aqueous
environment conﬁrm this organization [11, 12].
3.1.3. Lipophilic Permeability Barrier. Because lipid bilayers
are put together mainly by hydrophobic forces, these have
important biological eﬀects on them:
(i) lipid bilayers have an innate disposition to increase
their surface;
(ii) at some point, lipid bilayers will try to close them-
selves so that there are no loose ends with hydropho-
bic chains in direct contact with water molecules,
hence forming liposomes;
(iii) in case of a lipidic gap, bilayers maintain themselves
by ﬁlling it since a breach in the membrane is
energetically unfavourable.
Studies carried on the permeability of lipidic membranes
show that these bilayer membranes have a very low perme-
ability for ions and almost all polar molecules [13]. Water
molecules however are noted to traverse the membranes
quite easily, perhaps due to their small size, high concen-
tration, and absence of net charge. Moreover, there is a
great variation to the permeation speed among diﬀerent
molecules. For instance, tryptophan (a zwitterion at pH 7)
crosses the membrane 1000 times as slowly as does indole, a
moleculewithaverysimilarstructure,onlyneutral.Actually,
the permeability coeﬃcient of small molecules corresponds
to the diﬃculty these molecules face when they attempt to
shed their aqueous cover and adopt a lipophilic one. The less
energetically unfavourable this change is, the more easily a
molecule can traverse the membrane.
3.1.4. Chemical Instability. Liposomes can be chemically
degraded either because of hydrolysis of their ester groups or
because of lipid peroxidation (Figure 5). Hydrolysis depends
on temperature, pH, and the conﬁguration of lipids in the
membrane [14]. Peroxidation occurs when the environment
of lipids contains highly active regents such as heavy metals.
Adjusting the pH at 6.5, keeping the temperature low, and
protecting liposomes in an inert atmosphere should prevent
chemical degradation [3, 8].
3.2. Physical Traits.
3.2.1. Lipid Bilayer Phase Behavior. One of the most sig-
niﬁcant properties of any kind of lipids is the eﬀect of
temperature on their mobility. This response to temperature
changes is known as the phase behaviour of lipids. When
temperature rises, lipids pass from the solid phase to liquid
phase. The temperature at which lipids reversibly transition
from one phase to another is called transition temperature.
There is also an intermediate phase, interposed between
solid and liquid phase. The main diﬀerence between the two
extreme phases is the freedom lipids may have to diﬀuse
within the layer: trading places with by-standing lipids and
travelling along the lipid bilayer only occur in liquid phase.
However, a lipid rarely relocates from the lipidic sheet it
belongs to the opposing one, since it is diﬃcult for its polar
head to traverse through the hydrophobic core of the bilayer
[15].
3.2.2. Stability of Lipidic Membranes. The stability of lipidic
membranes is aﬀected by plenty variables. Firstly, lipo-
somes gain mobility as temperature rises and that greatly
inﬂuences the stability of their membrane, given that it is
more penetrable and sensitive when being in liquid phase.
Therefore, the encapsulation properties of the liposomes
vary along with temperature ﬂuctuations [16]. Also, the
ingredients of a liposomal membrane can aﬀect its stability.
When it comes to phospholipidic liposomes, the use of an
auxiliary molecule like cholesterol is highly advised as it
has been shown to rigidify the membrane. The presence of
polymers like polyethylene glycol (PEG) prevents them from
aggregating and fusing, among other things [3, 17]. Finally,
the lipidic polar head that is exposed to the aqueous medium
surrounding the liposomes can be subjected to pH changes
that potentially alter its charge and hydration state [18].4 ISRN Pharmaceutics
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Figure 5: The process of lipidic peroxidation.
3.2.3. Size Dispersion. Liposomes are vesicles featuring a
diameter of a few dozens to a few thousands nanometers.
Sincetheycanincorporateoneormorephospholipidicbilay-
ers separated by one or more internal aqueous departments,
it is easily understood that the more concentric bilayers exist,
the greater the diameter of the liposome will be. Liposomes
are diﬀerentiated according to their size into “Multilamellar
Large Vesicles” (MLVs), “Small Unilamellar Vesicles” (SUVs)
of 40 to 100nm of diameter, “Large Unilamellar Vesicles”
(LUVs)of100to500nmofdiameter,and“GiantUnilamellar
Vesicles” (GUVs) of 500 to 100µm of diameter [3, 8, 19].
3.2.4. Net Surface Charge. In general, the liposomal mem-
branes can appear to be overall neutral, positively or
negatively charged. Their net charge aﬀects their behaviour
in vivo. More particularly, negatively charged liposomes
circulate for a shorter time in the blood stream compared
to the neutral ones. Furthermore, those that are posi-
tively charged appear to be more toxic [4, 9]. However,
experiments that involved the formulation of a negatively
and a positively charged batch of liposomal amphotericin-
B returned comparable tissue distribution values for both
groups [20].
3.2.5. Colloidal Instability. In case electrostatic interactions,
steric properties, and hydration forces that exist between
liposomes allow it, then they have a tendency to aggregate
and fuse. Consequently, it depends on the resultant of the
aforementioned forces to keep the membranes of liposomes
from pressing against each other and potentially merging
(Figure 6)[ 3].
3.3. Pharmacokinetics of Liposomes
3.3.1.PharmacokineticsOverview. Pharmacokineticsoflipo-
somes focuses on their distribution throughout the body
Unfused
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Figure 6: Colloidal instability of liposomes. When two or more
liposomes come close enough, their lipidic membranes can interact
in two diﬀerent ways: they can either merge only with their outer
lipid sheet (bottom left) or can fuse their entire membranes,
essentially blending their contents (bottom right) [6].
ﬂuids and tissues, their metabolism, which mainly includes
their chemical degradation, and their excretion, which basi-
cally copes with the uptake of liposomes by the mononuclear
phagocyticsystem(MPS)andtheirclearance.Oneimportant
goal reached by liposomal formulation is the alteration of
the pharmacokinetic proﬁles of drugs [21]. When agents are
carried within liposomes, they actually adopt their carrier’s
pharmacokinetic disposition until the moment they are
released from them. As a result, liposomes have the ability to
change both the tissue distribution and the rate of clearance
of the drug they carry. Apparently, liberation of the drug
from its transporter is required in order for it to exert any
therapeutic action. Any drug molecules trapped inside the
liposomalcoreorotherwisestillconnectedtothatmoietyare
practically inert [22, 23].
The pharmacokinetic behaviour of liposomes is mainly
determined by their physiochemical properties along with aISRN Pharmaceutics 5
series of various other factors. Their physical and chemical
traits have been reviewed in a previous section. Here-
inafter follows a brief presentation of factors that relate to
their administration, metabolism, and release of the active
ingredient. One should highlight though that the exact
mechanisms through which these parameters act upon and
determine the ﬁnal pharmacokinetic proﬁle of each drug are
yettobefullyunderstood.ProducingaccuratePKmodelsfor
liposomes and the drugs they carry is a strenuous and time-
demandingprocedure.Thetotalconcentrationofamedicine
in the plasma is found under three diﬀerent forms: the free-
formmedicinewhichisthedrugmoleculesthathaveescaped
their liposomal carriers, the liposomal form, which is the
concentration of drug still trapped inside the liposomes,
and, ﬁnally, the plasma protein-covered medicine [3, 24].
The proportion at which these forms coexist in vivo at any
given time depends on the stability of liposomal carriers
and the nature of the encapsulated molecule. However, we
are only interested in monitoring the biopharmaceutical
behaviour of the free-form medicine that derives directly
from the liposomes. Sadly, that is not always simple or even
feasible, either because we cannot distinguish the origin
of each form or because we cannot monitor them in the
microenvironment of some tumoral sites [25].
3.3.2. Diﬀerent Administration Routes. Intraperitoneal (I.P.)
and intravenous (I.V.) administration tend to have the
same eﬀect on mice as well as rats. In I.P. administration,
liposomes ﬁrst enter the lymph and afterwards the blood
stream. The only expected diﬀerence between I.P. and I.V.
introduction of liposomes to the organism is a small lag
noticed before the ﬁrst traces of drug show up in the blood
after an I.P. administration.
In Vivo Distribution of Liposomes. Once inside the organism,
the fate of liposomes depends on their stability in the blood
stream as well as their ability to enter various tissues. The
former factor is aﬀected by the liposomes quantitative and
qualitative composition and their size. Moreover, in the
blood stream liposomes interact with plasma proteins, such
as opsonins and high- and low-density lipoproteins (HDLs
and LDLs, resp.). Opsonins help MPS recognize and elim-
inate liposomes while HDL and LDL cause rearrangements
on their outer lipid layer. These rearrangements usually lead
to a rapid release of the enclosed drug to the plasma [26].
3.3.3. Elimination of Liposomes. Elimination of liposomes
takes place through three diﬀerent routes. The ﬁrst one
involves the capture and elimination of liposomes by the
MPS. This event results in the excretion of the active
ingredient at a hepatic level and its subsequent metabolism,
although a small portion of it could reenter the blood circu-
lation. The second elimination route deals with the escape
of the active ingredient from circulating liposomes which
inevitably leads to greater tissue distribution, metabolism,
and excretion for the drug. Finally, there is the passage of
liposomes to the tumoral tissues and their local metabolic
elimination, a route which is the least favoured of all [27].
3.3.4. Hepatic Adventures. The absorption of plasma pro-
teins on the membrane surface of liposomes causes their
opsonization that consecutively leads to their recognition by
the MPS, to their accumulation to the liver, and ﬁnally to
their metabolism by specialized MPS cells called Kuppfer
cells. In addition, liposomes are metabolized by splenic
macrophages [28].
3.3.5. Release of the Active Ingredient. The kinetics according
to which the encapsulated active ingredient traverses the
lipid bilayer and exits from its liposomal container depend
on the nature of the lipidic membrane and its interactions
with the encapsulated drug. The mechanism of release can
be described in three steps: the absorption of the active
ingredient in the inner lipid layer of the liposome, its diﬀu-
sion through the membrane, and, ﬁnally, its excretion to the
surrounding environment. The eﬃcacy of this mechanism
depends on the ﬂuidity of the lipid bilayer and on the
kind of encapsulated molecule (size, partition coeﬃcient in
oil/water).
3.3.6. Delivery of the Active Ingredient to Target Cells. The
delivery of the active ingredient requires an interaction
between the carrier of the drug and the target cell. Of
course, whether the drug is required to be released to the
extracellular ﬂuid (ECF) or inside the targeted cell depends
on the mechanism of release and the architecture of the
carrier [29, 30]. Generally, there are ﬁve distinct ways that
lead to the liberation of the drug and its disposition to the
target cell [3, 31].
(1) The ﬁrst way involves the absorption of liposomes
on the membranes of cells where usually after a
long period of time, the lipid bilayer of the carrier
is degraded by factors like enzymes, lipases, or
mechanical strain. That results in the liberation of
the active ingredient to the ECF, where they can be
diﬀused towards the cytoplasm—a process that can
be especially problematic for hydrophilic molecules.
Itshouldbepointed outthatoncethedrughasleftits
carrier, its pharmacokinetic disposition is the sameas
to that of the free-form drug.
(2) A more straight-forward approach involves the
fusion of the liposomal membrane with that of the
target cell, hence causing the liberation of the entire
liposomal content directly into the cytoplasm.
(3) The third and most frequent way is that of endo-
cytosis eﬀectuated by a receptor. This process only
regards vesicles of a maximum diameter of 150nm
and active ingredients that can withstand the acidic
environment of the lysosomes, the organelles where
after the endocytosis liposomes are enzymically pro-
cessed.
(4) The means of phagocytosis concerns liposomes of
a size superior to 150nm and is accomplished
by speciﬁc cells of the immune system, such as
monocytes, macrophages, and Kuppfer cells.6 ISRN Pharmaceutics
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Figure 7: Liposome modulated for drug delivery. In this graphic
representation, apart from the basic liposomal structure, one can
also observe the protective polymers grafted to the lipid bilayer
(upper left), peptides conjugated with lipids for directing the
liposome to a certain target (right), a lipophilic molecule soluble
in the lipid bilayer, and polar content soluble in the aqueous core.
(5) Finally, the ﬁfth way involves the transfer of a usually
lipophilic active ingredient from the liposomes to the
phospholipidic plasma lipoproteins because of the
greataﬃnitybetweentheformer’sbilayerwithlatter’s
monolayer.
3.4. Liposomes as Drug Carrier Systems. Signiﬁcant progress
has been achieved in the development and use of carrier
vehicles delivering pharmacologically active molecules to
tumoral sites over the past decade. Nowadays, the main types
of carrier-mediated anticancer agents are indeed liposomes;
they are used either alone or conjugated with certain other
agents. In theory, the assets of liposome-mediated drugs are
greater solubility, longer circulation times, greater exposure,
and focused delivery for the enclosed drug (Figure 7). They
also provide better therapeutic index and the possibility to
bypass resistance related to the free-form of drugs [32].
Hereinafter follows a presentation of the various types of
liposomes that have been engineered since that ﬁrst became
feasible, at around 1980. The way liposomes addressed the
problemsofclassicchemotherapyandhowscientistshandled
the drawbacks and limitations of each type of liposomes is
also reviewed.
3.4.1.ConventionalLiposomes. Conventionalliposomescon-
sist of phospholipids like phosphatidylcholine (PC), phos-
phatidylserine (PS), phosphatidylglycerol (PG), and car-
diolipin (CL) [2]. Liposomal formulation of various
active molecules handles the two major complications of
chemotherapy: limited biodistribution and lack of speciﬁed
targeting. Liposomes manage to protect the encapsulated
molecules from all types of rapid degradation (of enzymatic,
immunological, and chemical kind) and passively target
tissuesororgansthatdonothaveacontinuousendothelium,
like the liver, spleen, and bone marrow [4]. Another great
achievement was the undeniable increase in the solubility
of many amphiphilic and lipophilic antineoplastic agents,
such as 5-FU. Finally, clinical trials have showcased that
liposomal formulations reduce the span of side eﬀects for
certain drugs, as in the case of doxorubicin where a lower
risk of cardiotoxicity was noted [30, 33].
3.4.2. Pharmacological Impairments. Conventional lipo-
somes were a breakthrough in biomedical technology and
still hold a lot of promises for the future. However,
this ﬁrst generation has presented various problems and
pharmacological implications over the years. A profound
comprehensionofthesedrawbacksallowsresearcherstotone
them down or even bypass them, thus creating more and
more eﬀective types of liposomes.
A main drawback of conventional liposomes is their
quick capture by the MPS [34]. Occasionally, this is a
desired outcome: high concentration of speciﬁc drugs in
the MPS can help battle local infections. In most cases,
however, the capture of liposomes by the MPS and their
removal from blood circulation hampers their therapeutic
eﬀect [3, 4]. For the uptake of liposomes by MPS the
binding of serum proteins to their surface is required. These
are called opsonins and include various protein types, like
immunoglobulins and ﬁbronectin among others. A chemical
signal for MPS uptake is the complement components as
well. Complement system is part of the innate immune
system of an organism that directly deals with every sub-
stance regarded as a pathogen. It also incorporates various
proteins and acts through commencing membrane lysis and
facilitating liposomal uptake by the MPS. Surprisingly, the
discovery of certain serum components called dysopsonins
brought into the light an unexpected ally in the battle against
MPS. Human serum albumin and Immunoglobulin A (IgA)
actually constraint liposomal recognition and phagocytosis
[4].
3.4.3. HDL and LDL. Blood circulating HDL and LDL
interact with liposomes and reduce their stability. Lipid
transfers and rearrangements take place on the liposomal
surface, frequently resulting in lipid depletion, generalized
disintegration of liposomes, and loss of the encapsulated
active ingredient [3, 7].
3.4.4. The Art of Problem Solving. In their eﬀorts to address
the aforementioned problems, scientists came up with
various techniques. Cholesterol (CH) is a hydrophobic
molecule and is therefore directed at the core of the
membrane,reinforcingit(Figure 8)[16].Thedenserpacking
of phospholipids caused by an excess of cholesterol (more
30%) eﬀectively reduced their transfer to HDL and LDL.
So, the addition of CH in the lipidic bilayer lowered their
permeability and increased their in vivo and in vitro stability.
Moreover, the use of PC with saturated fatty acyl chains
and materials that stretch transition temperature beyond
37◦C[3]o ﬀeredanevengreaterstabilization.Experimenting
with variations in liposomal size, researchers also observed
that liposomes smaller than 100nm in diameter (i.e., SUVs)
interacted less with plasma proteins, evaded capture by the
(MPS), had a greater circulation time, and accumulatedISRN Pharmaceutics 7
Figure 8: Cholesterol.
passively at the tumoral site eventually. Conversely, it was
found that larger liposomes (i.e., MLVs) were eliminated
more rapidly from blood circulation and did not manage to
avoid MPS uptake for as long as SUVs did. However, a small
size also involved reduced storage capabilities. So, a size of
80 to 200nm is nowadays considered to combine satisfactory
reservoir capacities without sacriﬁcing bioavailability.
3.4.5. Long-Circulating Liposomes. Despite all hopes placed
on conventional liposomes, they too were ﬁnally opsonized
and thus recognized by the MPS. Because of a great blood
supply and large population of local phagocytic cells, the
organs in which they accumulate are the liver and spleen
[30]. Mindful that hepatic and spleen accumulation of
liposomesisusuallyanunwantedoutcomethatalsoincluded
depletion and modiﬁcation of the inherent defensive proper-
tiesofphagocytes,scientistsembarkedonrenderingthelipo-
somes invisible to macrophages [35]. The concept of steric
repulsion against opsonizing proteins by placing hydrophilic
polymers (i.e., PEG) on the membrane surface of liposomes
yields a new category of liposomes called “long-circulating
liposomes”, also known as “sterically stabilized liposomes”
(SSLs). SSLs are essentially an evolution of conventional
liposomes: they are based on the same theory of carrier-
mediated drug delivery and feature some characteristics
proven to be indispensable, like high CH concentration
(40–50% mol/mol) and usually hydrogenated phospholipids
[24, 36].
(a) Polyethylene Glycol. PEG (CAS number 25322-68-3)
is a linear polyether diol. Its properties include good
biocompatibility,highsolubilitybothinaqueousandorganic
solutions, absence of toxicity, and very low stimulation of the
immunesystem(Figure 9(a))[37,38].PEGpolymericchains
are ﬂexible and have been noted to extend approximately
5nm from the liposomal surface [23], although this value
may be increased up to 10% of the diameter of the liposome.
Inaddition,thechainscanbeeasilymodiﬁed,lengthwiseand
weightwise. Modiﬁcation of liposomes with PEG can take
placethroughthreediﬀerentmethods.Firstly,themembrane
can physically absorb the polymer and place it among
its lipidic contents on account of its long apolar chains.
Secondly, provided that the polymer is present during the
formulation process, it can be incorporated in the newly
formed membrane. Finally, PEG can be anchored in the
lipidic bilayer by a cross-linked lipid (a covalently attached
polymer chain to the amine group of a phosphoglyceride),
like PEG-distearoylphosphatidylethanolamine (DSPE-PEG).
“Polymer Brush” is characterized by an extensive structure
that reaches up to 50 ˚ A from the liposomal surface. “Polymer
Mushroom” is a bit more compact form, while “Polymer
Pancake” occupies the least space (15 ˚ A) with a structure that
lays ﬁrmly on the liposomal surface. The various proposed
distributions of PEG chains in the lipidic membrane and the
space they occupy are represented in Figure 10. PEG chains
bring upon plenty enhancements for liposomes. Because of
steric repulsion, which also applies between liposomes, PEG
promotes their colloidal stability by inhibiting their aggre-
gation and fusion. Most importantly, though, this polymer
eﬀectively reduces MPS uptake of liposomes, potentiating all
of their related biopharmaceutical properties [39].
(b) PEG-Coated Liposomes and MPS Uptake. PEG chains
compose a protective, hydrophilic ﬁlm on the liposomal
membrane. Its presence acts as a spatial barrier for other
molecules that approach liposomes, like various serum
components. Because of the steric hindrance induced by the
polymer ﬁlm, interactions between liposomes and plasma
proteins are inhibited. In other words, liposomes are not
opsonized nor aﬀected by complement components and
consequently evade capture by MPS cells. Interestingly, the
ability of PEG to ameliorate liposomal circulation time is
usually proportionate to its amount and molecular weight or
length [40].
The practical outcome of these phenomena is obvious
when comparing the biopharmaceutical proﬁles of SSLs and
conventional liposomes: SSLs have a
(i) longer half-life (which leads to longer blood circula-
tion times),
(ii) improved tissue distribution (they are avoiding accu-
mulation in healthy tissues),
(iii) low systemic plasma clearance,
(iv) low volume of distribution and,
(v) multiple-fold greater Area Under the Curve (AUC)
values [30].
Summarizing, SSLs have PEG polymeric chains surrounding
their outer lipidic sheet and are rich in CH content (40–
50%mol/mol) and hydrogenated phospholipids [24]. Their
use has allowed encapsulated agents to present an improved
therapeutic index. This occurs because of the advanced
characteristics of SSLs that permit them to circulate longer in
the blood stream, in conjunction with the clearly augmented
permeability of the tumoral vascular system [41].8 ISRN Pharmaceutics
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Figure 9: The molecular type of polyethylene glycol (a) and chemical structure of DSPE-PEG (b).
Figure 10: Graphic representation of the two main shedding
concepts: (a) the enclosed drug is released to the ECF after PEG
polymers have unmasked the liposome upon arrival to the tumoral
siteand(b)targetingligandsarerevealedaftertheirpolymercoating
has been shed at the moment liposomes arrive to their target; now
they are able to interact with appropriate formations on the cell’s
surface.
3.4.6. Enhanced Permeation and Retention Eﬀect and Passive
Targeting. The phenomenon of Enhanced Permeation and
Retention (EPR) eﬀect describes the property of malignant
tissue to permit vesicles of proper size to traverse through
their vessel walls and enter the tumoral site. Pathological
tissues, such as inﬂammatory or solid tumour tissues, are
described by an increased vascular permeability [30, 42].
More particularly, solid tumours that undergo angiogenesis
develop discontinuous endothelium. Onto it, large fenes-
trations allow molecules of up to approximately 4000kDa
or 500nm to enter the interstitial space. SSLs fulﬁl the size
requirements needed to permeate the tumor vessels and
gather in the desired tissue. This phenomenon is called
passive targeting and involves the extravasation of liposomes
on account for their mechanical and physical properties.
More importantly, once liposomes have entered the tumoral
tissue, its malfunctioning lymphatic system is incapable
of removing them, so they are accumulated in this area,
granting time to the encapsulated liposomal load to exert its
therapeutic eﬀect [4].
3.4.7.ActiveLiposomes. Liposomesthatcanselectivelyrecog-
nize antigens or receptors situated on the surface of speciﬁc
cells are called “active liposomes” or “3rd generation lipo-
somes”.Sometimestumourcellsexpressmoietiesofproteinic
nature such as special receptors, transfer systems, and other
molecules on their membrane surfaces. If these formations
are within reach from the ECF, then speciﬁed recognition of
cancerous cells is possible by mating medicines with ligands
of great aﬃnity to the surface of targeted cells. Given that
there will be high selectivity towards the cancerous cells,
almost the entirety of administered drug will be accumulated
at the tumoral site, leaving nearly intact other healthy by-
standing cells. That way, the demanded dose for the same
cytotoxic result will be signiﬁcantly smaller when compared
tonontargetedtherapies.Practically,thisprovidesforabetter
therapeutic index with higher drug eﬃcacy and minimized
adverse eﬀects. Ligands appropriate for tumor targeting
are monoclonal antibodies (MAbs), peptides, carbohydrates,
glycoproteins, receptor ligands, and growth factors [43–45].
(a) Steady, Aim, and Fire: Monoclonal Antibodies and
Immunoliposomes. The mechanism of therapies based on
the use of MAb is bimodal. On one hand, MAb can act
directly upon speciﬁc receptors, stimulating or inhibiting
them.Thesereceptorsusuallycausesignalcascadesorinhibit
certain metabolic paths, either way leading to cell apoptosis.
On the other hand, a MAb can intervene and facilitate an
immunogenic response of the organism against cancerous
cells through IgG mediated procedures, like complement-,
antibody-, and cell-mediated cytotoxicity. Unfortunately, the
aforementioned technology has a major disadvantage. When
using free-form medicines, the more drug molecules are
mated with a MAb, the more sensitive the immunologic
system becomes against them. The solution to this mishap
may come once again from the ﬁeld of liposomes [46].
The coupling of liposomal carriers with MAb capable of
recognizing target cells directs the liposomes to the tumoral
site, binds them on the surface of the diseased cells, and
helps introduce either the liposomes or the enclosed drug
to their cytoplasm. When it comes to using antagonistic
antibodies, one can either “plant” them in the lipid bilayer of
liposomes or position them at one end of the PEG chains—
this last option presenting the beneﬁt of stealth, as well.
The resulting liposomes are called immunoliposomes and
have been put to the test giving very encouraging results.
Of course, the risk of immunoliposomes to be discovered
by an organism’s immune system still remains. Therefore,
in order for them to function eﬀectively, the amount of
antibodies placed on their surface must be enough for them
to bind to target cells but should not reach the level at which
their camouﬂage is compromised. Immunoliposomes have
proven to be quite potent and indeed present a wide array of
advantages, especially when compared to targeted free-form
medicines [23, 47].ISRN Pharmaceutics 9
(i) One can regulate the amount of ligand molecules
positioned on the liposomal surface thus pitching the
size of uptake.
(ii) They increase the quantity of drug that can be trans-
ferred to the target.
(iii) They present the “by-standing killing” eﬀect, mean-
ing that drug molecules can diﬀuse towards nearby
cells and express their cytotoxic action there as well.
(iv) Reduced interactions with nontargeted elements give
immunoliposomes a favourable pharmacokinetic
behavior.
(v) Precise action on targeted cells ensues drug eﬃcacy
and safety.
(vi) Finally, immunoliposomes are characterized by all
properties that make liposomal carriers ideal vectors:
they protect their content and do not easily arouse
immunologic response from the receiver organism.
(b) Phage-Liposomes. Because of the technical limitations
one may encounter when anchoring MAbs on liposome
(e.g., yield, cost eﬀectiveness) and the potentially limited
stability of the resulting immunoliposomes, novel alter-
native approaches for ensuring better targeting towards
speciﬁc tissues are being developed. Integration of phage
display technology is a promising strategy to achieve selec-
tive delivery of liposomes to tumors. Phage display has
allowed identiﬁcation of tumor-speciﬁc peptides, but as for
immunoliposomes, preparation of phage peptide-targeted
liposomes has some serious technical limitations [48]. Using
landscape phage fusion coat proteins has being recently
proposed as targeting ligands for liposomes. The property
of phage coat protein to insert spontaneously into liposome
bilayer can be used to generate easily phage-liposomes, thus
skipping the conjugation process [49]. Because selection
of tumor-binding ligands with phage display libraries is
an increasing and promising technology, developing phage-
liposomes should in the near future oﬀer challenging oppor-
tunities to improve delivery of anticancer drugs entrapped in
nanocarriers [50].
3.4.8. Sheddable Coatings. As mentioned before, steric sta-
bilization of liposomes is an indispensable method for
achieving longer circulation times and giving the carrier the
opportunity to extravasate to the tumoral site. Moreover,
ligands with high aﬃnity for formations located on the
membrane of cancerous cells oﬀer high selectivity towards
these cells, potentially ameliorating the drugs’ therapeutic
index [51, 52]. However, there is room for improvement
in both techniques. On one hand, steric stabilization can
sometimes render the liposomal bubble to be too rigid. So,
even though liposomes will withstand circulation strains and
have enough time to accumulate at the tumoral site, they
will not be able to loosen their structure and allow the
entrapped drug to exit. On the other hand, once ligands used
for targeting therapies, evasive against the immune system
though they are, are spotted, the entire therapy is rendered
useless [53–55]. A proposed solution for both sterically
stabilized and active liposomes can be sheddable coatings.
Sheddable coatings include molecules for covering the
entire liposomes, ligated to the liposomal surface in a
reversible way. In the case of SSL, the coating that needs to
be shed is apparently the PEG polymer chains. The shedding
should take place in the desired point in time, which is right
after liposomes have gathered in the malignant tissue. Then,
according to one of the techniques that will be presented
later, PEG chains unmask the liposomes, who are left to
diﬀuse their content in the ECF ﬂuid. As far as targeted
liposomes are considered, their targeting ligands could be
covered by an appropriate polymer. That way, immunologic
response will be hopefully diminished. This approach seems
to be hampering the targeting advantages of these moieties
since they will be covered underneath a polymer coat.
However, this method also ensures that this liposomal mask
will be removed the appropriate time, allowing ligands to
interact with their targets [47].
(a) Shedding Techniques. Shedding by removing link
between the stabilizing polymer and its liaison: these are
the three main ways to unshed liposomes through linkage
removal.
( a . 1 )A c i dp H - I n d u c e dS h e d d i n g .Receptor-mediated endo-
cytosis is a very common process by which liposomes enter
the cells. Liposomes are thus introduced to the lysosomal
and endolysosomal compartment where pH is around 4.5
and 5.5–6.0, respectively. Cytoplasmic pH could also be
more acidic than normal, when it comes to cancerous and
inﬂammatory tissue. If this is the case, then a pH-sensitive
linker between the lipids and polymer coating could undergo
protonation, hence hydrolyzing and removing the polymer
molecule [18].
(a.2) Reduction-Based Shedding. Carriers can also be con-
jugated with coatings via a linkage sensitive to red-ox
potential ﬂuctuations. The disulﬁde bond (–S–S–) is one of
these links. This particular bond is reversible but stable in
extracellular environments. However, the high intracellular
concentration of molecules presenting sulfhydryl groups
creates a reductive environment for the disulﬁde bond. Its
reductioncouldalternativelytakeplaceatthecellsurfaceand
at the endosomal and/or lysosomal department by local red-
ox enzymes [18].
(a.3) Proteolysis-Generated Shedding. In case the link
between the polymer coat and its anchor is a peptide,
then proteolytic enzymes can hydrolyze it, hence freeing
the liposome from its cover. This technique can be put in
use since proteolytic enzymes are abundant in the ECF of
inﬂammatory and malignant tissues. Of course, proteolytic
enzymes are also available intracellularly in organelles like
endosomes and lysosomes [47].
(a.4) Shedding by Self-Degradation of the Coating Polymer.
Instead of breaking the link between the coating and its10 ISRN Pharmaceutics
anchor, a proposed technique involves the full degradation
of the polymer. For this to take eﬀect, coatings must be fully
biodegradable though still invisible to the immune system.
One solution included chemically modiﬁed PEG molecules
so as to be sensitive in red-ox changes [47, 56].
4. Conclusions
Developing innovative delivery strategies for optimizing
therapeutics is an ongoing story. Despite constant eﬀorts
made by pharmaceutical and biotechnology companies, it
is fully acknowledged now that brand-new pharmacological
targets will hardly emerge in the future. Consequently,
achieving noninferiority during phase-3 clinical trials is now
accepted by most regulatory agencies when approving new
chemical entities. In this context, looking backwards to old
drugs with new delivery systems is more and more seen as a
possiblealternativetofurtherincreasebothdrugeﬃcacyand
tolerance, and in this respect, nanomedicine is a promising
newﬁeldofin v estigation[3].Althoughbeinganoldconcept,
moving towards liposome-encapsulated drugs is still consid-
ered as one of the most challenging opportunity to optimize
clinicaloutcomeinvariousdiseases,withstrongexpectations
in oncology. Because of their tolerability and similarity with
natural, biological membranes, liposomes are less likely to
be concerned by the issue of long-term accumulation in the
body, as for other emerging nano-objects [57]. Recent eﬀorts
madetodeveloptargetedliposomes(e.g.,immunoliposomes
or fusion phage liposomes) will probably yield, in the near
future, a new generation of drugs with unique properties
enhancing the eﬀectiveness of drug-based therapy.
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